Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454805 · ClinicalTrials.gov registry record · Phase 2
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00454805 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 75 participants.
The verdict
NCT00454805, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.
Interventions
- DRUG Fulvestrant
- DRUG AZD2171
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-03 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454805
The ClinicalTrials.gov registry entry for NCT00454805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT00454805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00454805 about?
NCT00454805 is a clinical study titled "AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.". The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.
What is the current status of trial NCT00454805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2007-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT00454805?
The interventions under investigation include: Fulvestrant (DRUG), AZD2171 (DRUG).
Who is sponsoring clinical trial NCT00454805?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.